On her website on 17 September 2014, Mrs. Willmott stated that “we must ensure the industry is transparent and works in the interest of patients. This legislation will go a long way to achieving that and I look forward to taking it further in the coming months” She also expressed concern that the responsibility for medical devices policy will not fall under the auspices of DG Enterprise, following a decision by Mr. Junker which is being increasingly criticized by key EU stakeholders. As rapporteur for the Clinical Trials Regulation and a long-standing health-focused MEP, Mrs. Willmott was one of three main MEPs tipped to be the next Rapporteur of the MDR who will take over from ousted MEP Ms. Dagmar Roth-Behrendt (S&D, Germany). The other two potential MEPs that were suggested were Ms. Linda McAvan (S&D, UK) and Ms. Christel Schaldemose (S&D, Denmark). While Ms. Willmott did not take a central role in the discussions on the Medical Devices Regulation during the previous Parliamentary term, her focus during the Clinical Trials Regulation was on improving transparency and safety for patients.
[Read the rest of this article...]